The Global Sjogren’s Syndrome Market Growth Accelerated By Rising Prevalence Of Sjogren’s Syndrome.
Sjogren's syndrome is an autoimmune disease that causes dryness in the mouth
and eyes due to lack of tears and saliva. The prevalence of this syndrome is
increasing with rising environmental pollution and other factors. This has
increased the demand for medications managing dry eyes and mouth, tear and
saliva substitutes, and devices monitoring dryness levels associated with
Sjogren’s syndrome.
The global Sjogren’s
Syndrome Market is estimated to be valued at US$ 242.81 Mn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of Sjogren's syndrome driven by environmental factors
has accelerated the demand for therapeutics and diagnostic tests for early
detection and management of the disease. The rising awareness about Sjogren's
syndrome symptoms and available treatment options has further propelled the
market growth. Various government and non-profit organizations are funding
research on developing novel drug formulations and diagnostic biomarkers which
will possibly drive the market during the forecast period.
Segment Analysis
The global Sjogren's Syndrome market is dominated by the primary Sjogren's
syndrome segment which accounts for nearly 70% share of the overall market.
Primary Sjogren's syndrome arises independently without any other connective
tissue disease and is characterized by dry eyes and dry mouth along with
symptoms of fatigue, joint pain and dryness in other parts of the body.The high
prevalence and extensive manifestation of symptoms have made primary Sjogren's
syndrome the dominating sub-segment in the market.
Key Takeaways
The global Sjogren’s
Syndrome Market Share is expected to witness high growth during the
forecast period of 2023 to 2030. The global Sjogren’s Syndrome Market is
estimated to be valued at US$ 242.81 Mn in
2023 and is expected to exhibit a CAGR
of 6.5% over the forecast period
2023 to 2030.
Regional analysis
North America accounts for the largest share in the global Sjogren's Syndrome
market owing to high awareness levels regarding the disease, established healthcare
infrastructure and presence of key market players in the region. Europe is the
second largest regional market. However, Asia Pacific is expected to witness
the fastest growth during the forecast period due to growing geriatric
population, improving access to healthcare services and increasing expenditure
on healthcare.
Key players
Key players operating in the Sjogren's Syndrome market are Abcam plc, Bio-Rad
Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo
Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck
KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa
Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex,
Inc., MBL International Corporation.
Get More Insights On This Topic: https://www.pressreleasebulletin.com/the-global-sjogrens-syndrome-market-driven-by-increasing-prevalence-of-autoimmune-disorders/
Comments
Post a Comment